Investigating the role of PI3 kinase in Myelodysplastic Syndrome
Official title: PI3 Kinase Inactivation in Myelodysplastic Syndrome
Funded at Albert Einstein College of Medicine · NIH-11112391 · Data updated 2026-11-12
This study is looking at how certain changes in genes might affect blood cell production in older adults with Myelodysplastic Syndrome (MDS), and it hopes to find new ways to help improve treatment for people with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project start | September 1, 2022 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $558,965 |
| NIH project number | 5R01DK130895-04 |
| Project ID | NIH-11112391 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults diagnosed with Myelodysplastic Syndrome or those exhibiting symptoms related to blood cell deficiencies.
✕Less likely to help
Patients with other forms of blood disorders or those who do not have Myelodysplastic Syndrome may not benefit from this research.
What this research studies
This research focuses on Myelodysplastic Syndrome (MDS), a disorder that affects blood cell production, particularly in older adults. The study examines how mutations in RNA splicing factors and the PI3K/AKT signaling pathway contribute to the disease. By using mouse models, researchers aim to understand the mechanisms behind impaired blood cell differentiation and genomic instability in MDS. The goal is to explore potential therapeutic approaches that could improve patient outcomes by targeting these pathways.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve blood cell production and overall health for patients with Myelodysplastic Syndrome.
How similar studies have gone: Previous research has shown promising results in targeting the PI3K/AKT pathway for blood disorders, indicating potential for success in this approach.
Where this research is happening
-
Albert Einstein College of Medicine
Bronx, United States Active
Researchers
- Principal investigator: Gritsman, Kira — Albert Einstein College of Medicine
- Study coordinator: Gritsman, Kira
Related research
Other NIH-funded projects on the same topics.
-
Targeting diverse stem cells in myelodysplastic syndrome to eradicate the disease
Aimed at identifying weaknesses in the diverse stem cell populations of myelodysplastic syndrome so future treatments can wipe out the root cause of the disease.
-
New treatment approach for myelodysplastic syndrome and acute myeloid leukemia
This project aims to develop a new antibody-based therapy to help people with MDS or AML, especially older or frail patients who cannot tolerate high-dose chemotherapy.
-
Targeting metabolic weak spots in myelodysplastic syndrome stem cells
The team is trying metabolism-based treatments to kill the stem cells that drive high-risk myelodysplastic syndrome (MDS).
-
Identifying harmful and harmless genetic variations in blood cancer predisposition genes
This study is looking at how certain changes in a gene called DDX41 might affect the chances of developing blood disorders like myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), so that doctors can provide better advice and support for patients at risk.
-
Investigating CCRL2's role in myelodysplastic syndrome
This study is looking at how a specific gene called CCRL2 affects the growth of harmful cells in myelodysplastic syndrome (MDS), especially in men, to find new ways to improve treatment for people with this blood disorder.
-
Understanding how immune evasion occurs in high-risk myelodysplastic syndrome
This study is looking at how a protein called VISTA helps high-risk myelodysplastic syndrome (HR-MDS) avoid being attacked by the immune system, with the goal of finding new ways to improve treatments for patients like you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.